Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Kenalog (injectable), Nasacort (intranasal), Aristocort (topical), Trianex (1)

Analgesic (2) · Opioid (2) · Prodrug (1) · [[:Category:Corticosteroids|Corticosteroid]] (1) · [[:Category:Glucocorticoids|Glucocorticoid (intermediate-acting)]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000661-QINU`"', '"`UNIQ--vote-00000662-QINU`"', '"`UNIQ--vote-00000663-QINU`"', '"`UNIQ--vote-00000664-QINU`"', '"`UNIQ--vote-00000665-QINU`"' (1)

None (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Topical 0.025-0.5% cream/ointment BID; intra-articular 5-40 mg per joint q3-6 months; intranasal Nasacort 110 mcg/spray, 2 sprays/nostril daily; oral paste 0.1% to lesion 2-3×/d (1)

None (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Topical creams, ointments, lotions, dental paste (0.025-0.5%); Kenalog 10 mg/mL, 40 mg/mL injection; Nasacort 55 mcg/spray intranasal; oral inhaler discontinued in US (1)

None (1) · 360 mg/day (1) · Indication-specific (1)

None (1) · intra-articular (1) · intralesional (1) · intramuscular (1) · intranasal (1) · oral paste (1) · PO (only formulation marketed in the US). (1) · Topical (1)

None (1) · 30–60 min (PO) (1) · Topical hours; intra-articular days to weeks (1)

None (1) · 4–6 hours (1) · Intra-articular 3-6 months (depot effect of acetonide microcrystals) (1)

None (1) · 2.5–3 hours (1) · Plasma ~3-5 hours; biologic effect substantially longer (~12-36 hours for intermediate-acting glucocorticoids)'"`UNIQ--ref-00000666-QINU`"' (1)

None (1) · Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Topical/intranasal generally low-risk; intra-articular and high-dose injection: weigh risk individually.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · OTC (lowest-strength topicals) and [[USLegal:Prescription only|Rx-only]] (higher strengths, injectable) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)